The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news

The Kidney Cancer Association Announces $1.3 Million in New Research Opportunities
HOUSTON–April 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce its Board of Directors recently approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. The application process opens on April 17 and closes on May 20. Award winners will be announced in the Fall of 2019.“The KCA Board of Directors is committed to providing research funding with the goal of identifying new treatments and finding new ways to prevent and manage the disease,” said Christopher Wood, Board President.“With these advancements in research and a greater...
Source: Kidney Cancer Association - April 16, 2019 Category: Urology & Nephrology Source Type: news

The Kidney Cancer Association Appoints Kendall Monroe as CAO
HOUSTON– March 19, 2019– The Kidney Cancer Association (KCA) is pleased to announce that Kendall Monroe has joined the organization as its first Chief Advancement Officer (CAO). Monroe brings more than a decade of experience in development, fundraising and donor relations. Monroe most recently worked as the director of planned giving and board management with the University of St. Thomas. She previously held several positions within MD Anderson Cancer Center - including assistant director of development, associate director of development and director of trusts, estates and gift planning. Additional roles i...
Source: Kidney Cancer Association - March 21, 2019 Category: Urology & Nephrology Source Type: news

Joanne battles stage 4 kidney cancer
Four years ago, Joanne Romero, who lives in Texas, was diagnosed with stage 4 kidney cancer when she was 26 weeks pregnant. Despite her challenges, Joanne remains positive and hopes her story serves as an inspiration to others.   My journey began on Feb. 16, 2015. I was currently 26 weeks pregnant. I was experiencing a cough that continued to get worse. That day, I was scheduled to have a lung procedure to see what was causing the cough. My high-risk OB ordered an ultrasound the night before. She wanted to make sure my baby was doing well enough for the procedure. During the ultrasound, the ultrasound tech a...
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Dr. Marc-Oliver Grimm provided an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session
In this article, Dr. Marc-Oliver Grimm provides an overview of the many changes in the landscape for advanced renal cell carcinoma at the urogenital cancer treatment at a glance session.03/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 18, 2019 Category: Urology & Nephrology Source Type: news

Antibiotics Before Checkpoint Inhibitors Tied to Worse Survival
Use of broad-spectrum antibiotics 30 days before starting an immune checkpoint inhibitor was associated with a dramatic reduction in cancer patients' survival, a prospective study found.03/11/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 11, 2019 Category: Urology & Nephrology Source Type: news

Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer
The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to immune checkpoint inhibitors and novel combinations.03/07/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 7, 2019 Category: Urology & Nephrology Source Type: news

Toxicity, Clinical Outcomes of Varying Cabozantinib Dosage in Metastatic RCC
While clinical outcomes may be comparable in patients with metastatic renal cell carcinoma (RCC) who are treated with full vs reduced dose of cabozantinib, reduced dose may not be associated with decreased adverse events.03/06/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - March 6, 2019 Category: Urology & Nephrology Source Type: news